CSIR Central

Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors

IR@CDRI: CSIR-Central Drug Research Institute, Lucknow

View Archive Info
 
 
Field Value
 
Creator Murugesan, Vanangamudi
Makwana, Nandini
Suryawanshi, Rahul
Saxena, Reshu
Tripathi, Rajkamal
Paranjape, Ramesh
Kulkarni, Smita
Katti, S B
 
Date 2014-08-12T06:41:54Z
2014-08-12T06:41:54Z
2014
 
Identifier Bioorganic & Medicinal Chemistry, 2014, 22(12), 3159–3170
http://hdl.handle.net/123456789/1361
 
Description A series of novel thiazolidin-4-one analogues, characterized by different substitution patterns at positions C-2 and N-3 of the thiazolidin-4-one scaffold for anti-HIV-1 activity has been investigated. Most of the compounds showed anti-HIV-1 activity at micromolar concentrations when tested in TZM-bl cells in vitro. Among the thirty-three compounds tested, compound 16 was the most potent inhibitor of HIV-1 replication against HIV-1IIIB, HIV-1ADA5, HIV-1UG070 and HIV-1VB59 (EC50 = 0.02, 0.08, 0.08 and 0.08 µM, respectively) with selectivity index (SI = 6940, 1735, 1692 and 1692) against tested viral strains, respectively. The results of the present study suggested that the substitution of the nitro group at 6' position of the C-2 phenyl ring and 2'',6''-dimethylpyridin-2-yl at the N-3 position of thiazolidin-4-one had a major impact on the anti-HIV-1 activity and was found to lower cytotoxicity. The substitution of the heteroaryl ring with bromo group and bicyclic heteroaryl ring at N-3 thiazolidin-4-one was found to lower anti-HIV-1 activity and increase cytotoxicity. The undertaken docking studies thus facilitated the identification of crucial interactions between the HIV-1 RT enzyme and thiazolidin-4-one inhibitors, which can be used to design new potential inhibitors.
 
Format 890555 bytes
application/pdf
 
Language en
 
Relation CSIR-CDRI Communication No. 8660
 
Subject Thiazolidin-4-Ones
Anti-HIV-1 Activity
HIV-1 Reverse Transcriptase
NNRTIs
 
Title Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors
 
Type Article